CHALLENGES AND POLICY SUPPORTS IN INDONESIAN PHARMACEUTICAL RAW MATERIALS INDUSTRY
Background: Indonesian pharmaceutical industry is experiencing many challenges, spesficically their raw materials mostly are imported products. Several factors that cause the pharmaceutical raw materials industry to be challenging are lack of mastery of technology, lack of government support, low budget for R&D, high costs of development and time consuming, and low innovation incentives.
Aims: This study aims to conduct a study on the strategies for developing the pharmaceutical raw material industry in Indonesia
Methods: This study employed a qualitative method, the data triangulation gathered from interviews and discussions with several industries and institutions. The study was conducted for six months in 2022.
Results: The policies that are required to be implemented to make the pharmaceutical raw materials industry thrive are (i) the presence of a clear grand strategy, (ii) determining the priority of pharmaceutical raw materials based on industrial needs, (iii) protecting domestic products, (iv) increasing health spending, (v) strengthening basic chemical product, and (vi) increasing the budget for R&D.
Conclusion: Some policies that can be enhanced include providing incentives and policies that favor the local pharmaceutical raw material industry, ranging from regulated prices, putting an end to dependence on imported products, tax incentives, domestic products protection through import tariff policies, energy subsidies, technology transfers, et cetera.
Keywords: pharmaceutical raw materials, policy, pharmaceutical
Agency for the Assessment and Application of Technology (2020) Health Technology Outlook 2020. Jakarta-Indonesia.
Anggriani, Y. et al. (2020) ‘The Impact of Pharmaceutical Policies on Medicine Procurement Pricing in Indonesia Under the Implementation of Indonesia's Social Health Insurance System', Value in Health Regional Issues, 21, pp. 1–8. Available at: https://doi.org/10.1016/j.vhri.2019.05.005.
Atkinson, R.D. (2020) The Impact of China's Policies on Global Biopharmaceutical Industry Innovation. Information Technology & Innovation Foundation. Available at: https://itif.org/publications/2020/09/08/impact-chinas-policies-global-biopharmaceutical-industry-innovation/ (Accessed: 5 November 2023).
Ayubi, S. (2022) ‘The Role of SOE Healthcare Holding Company in Indonesia Healthcare Ecosystem'.
Barattieri, A. and Cacciatore, M. (2023) ‘Self-Harming Trade Policy? Protectionism and Production Networks', American Economic Journal: Macroeconomics, 15(2), pp. 97–128. Available at: https://doi.org/10.1257/mac.20190445.
Binekasri, R. (2022) ‘86,7% of Indonesian Population has Already join JKN Program'. Available at: https://www.cnbcindonesia.com/market/20220630130849-17-351778/867-penduduk-ri-sudah-jadi-peserta-jkn (Accessed: 9 May 2022).
BPS (2022) Indonesian GDP 2021. Badan Pusat Statistik. Available at: https://www.bps.go.id/indicator/11/106/2/-seri-2010-distribusi-pdb-triwulanan-seri-2010-atas-dasar-harga-berlaku.html (Accessed: 9 May 2022).
Castle, L. (2022) ‘Active Pharmaceutical Ingredient (API) Manufacturing: The Next Growth Driver of The Bangladesh Pharmaceutical Industry'. Available at: https://www.lightcastlebd.com/insights/2021/08/active-pharmaceutical-ingredient-api-manufacturing-the-next-growth-driver-of-the-bangladesh-pharmaceutical-industry/ (Accessed: 8 October 2022).
Chaabouni, S. and Saidi, K. (2017) ‘The dynamic links between carbon dioxide (CO2) emissions, health spending and GDP growth: A case study for 51 countries', Environmental Research, 158, pp. 137–144. Available at: https://doi.org/10.1016/j.envres.2017.05.041.
Cheng, L. et al. (2021) ‘Destruction and Deflection: Evidence from American Antidumping Actions against China', Structural Change and Economic Dynamics, 57, pp. 203–213. Available at: https://doi.org/10.1016/j.strueco.2021.03.009.
Coordinating Minister for Maritime Affairs and Investment (2021) ‘Investment Policy and Development of Integrated Industrial Estates for Pharmaceutical Industry'. Bali.
Ederington, J. and McCalman, P. (2011) ‘Infant industry protection and industrial dynamics', Journal of International Economics, 84(1), pp. 37–47. Available at: https://doi.org/10.1016/j.jinteco.2011.01.002.
EFPIA (2022) The Pharmaceutical Industry in Figures. Belgium: The European Federation of Pharmaceutical Industries and Associations.
Esparcia, C. and López, R. (2022) ‘Outperformance of the pharmaceutical sector during the COVID-19 pandemic: Global time-varying screening rule development', Information Sciences, 609, pp. 1181–1203. Available at: https://doi.org/10.1016/j.ins.2022.07.146.
Fang, Y. (2017) ‘Pharmaceutical Policy in China', in Z.-U.-D. Babar (ed.) Pharmaceutical Policy in Countries with Developing Healthcare Systems. Cham: Springer International Publishing, pp. 169–191. Available at: https://doi.org/10.1007/978-3-319-51673-8_9.
Franz, D.R. (2009) ‘Preparedness for an anthrax attack', Molecular Aspects of Medicine, 30(6), pp. 503–510. Available at: https://doi.org/10.1016/j.mam.2009.07.002.
Gamo, N.J. et al. (2017) ‘Valley of death: A proposal to build a "translational bridge” for the next generation', Neuroscience Research, 115, pp. 1–4. Available at: https://doi.org/10.1016/j.neures.2016.11.003.
Kanavos, P., Mills, M. and Zhang, A. (2019) Pharmaceutical policy in China [PDF]. LSE Consulting. Available at: https://doi.org/10.21953/LSE.FG2T522B8R1X.
Ke, X., Saksena, P. and Holly, A. (2011) The Determinants of Health Expenditure: A Country-Level Panel Data Analysis. World Health Organization, p. 4. Available at: https://www.r4d.org/wp-content/uploads/TransisitionsInHealthFinancing_DeterminantsofExpenditures.pdf.
Kesselheim, A.S. et al. (2019) ‘Pharmaceutical Policy in the United States in 2019: An Overview of the Landscape and a Venues for Improvement', in Stanford Law & Policy Review. England: University of Stanford, pp. 421–481.
Kimia Farma (2021) Annual Report: Kimia Farma to The Next level for Global Healthcare Company. Jakarta: PT. Kimia Farma, Tbk. Available at: https://www.kimiafarma.co.id/files/Lap_Tahunan/Laporan_Tahunan-2021.pdf.
Lim, H. and Rokhim, R. (2021) ‘Factors affecting profitability of pharmaceutical company: an Indonesian evidence', Journal of Economic Studies, 48(5), pp. 981–995. Available at: https://doi.org/10.1108/JES-01-2020-0021.
Liu, H. (2021) ‘The Impact of the Coronavirus on Chinese Pharmaceutical Industry':, in. 6th International Conference on Financial Innovation and Economic Development (ICFIED 2021), Sanya, China. Available at: https://doi.org/10.2991/aebmr.k.210319.010.
Mazzucato, M. (2018) ‘Mission-oriented innovation policies: challenges and opportunities', Industrial and Corporate Change, 27(5), pp. 803–815. Available at: https://doi.org/10.1093/icc/dty034.
Melitz, M.J. (2005) ‘When and how should infant industries be protected?', Journal of International Economics, 66(1), pp. 177–196. Available at: https://doi.org/10.1016/j.jinteco.2004.07.001.
Ministry of Health Republic of Indonesia (2022) ‘Indonesia Pharmaceutical Policy'. Jakarta, Indonesia.
Ministry of Health Republic of Indonesia, M. of (2020) Action Plan Directorate of Pharmaceutical Production and Distribution 2020-2024. Jakarta.
Ministry of Industry Republic of Indonesia (2021) ‘Increasing the use of domestic products through the Domestic Content policy'. Bali.
Ministry of Invesment Republic of Indonesia (2022) ‘Promising Potential in Indonesia's Pharmaceutical and Health Industry'. Available at: https://www.bkpm.go.id/id/publikasi/detail/berita/potensi-menjanjikan-di-industri-farmasi-dan-kesehatan-indonesia#:~:text=Menurut%20data%20dari%20Kementerian%20Kesehatan,18%20industri%20ekstraksi%20produk%20alami.&text=menjadi%20891%20perusahaan. (Accessed: 9 May 2022).
Ministry of Trade Republic of Indonesia (2022) ‘Indonesia Trade Balance May 2022'. Available at: https://www.kemendag.go.id/id/newsroom/press-release/mendag-zulhas-neraca-perdagangan-indonesia-mei-2022-surplus-usd-2-9-miliar-1 (Accessed: 9 June 2022).
Morgan, J.M. and Sterling, S. (2019) Lowering Drug Prices: A Blueprint for Reform. The Great Democracy Initiative. Available at: https://rooseveltinstitute.org/wp-content/uploads/2021/08/GDI_Lowering-Drug-Prices-Blueprint_201911.pdf.
Murshid, M.E. and Haque, M. (2019) ‘Bangladesh National Drug Policy 1982-2016 and Recommendations in Policy Aspects', Eurasian Journal of Emergency Medicine, 18(2), pp. 104–109. Available at: https://doi.org/10.4274/eajem.galenos.2019.43765.
National Agency of Drug and Food Control (2022) ‘Pharmaceutical Industry data In Indonesia That already had GMP Certificate'. Available at: https://www.pom.go.id/new/view/direct/industri-farmasi (Accessed: 9 June 2022).
Neshith Desai Associates (2023) The Indian Pharmaceutical Industry: Regulatory, Legal and Tax Overview. India: Neshith Desai Associates, p. 3. Available at: https://www.nishithdesai.com/fileadmin/user_upload/pdfs/Research_Papers/The-Indian-Pharmaceutical-Industry.pdf.
Ni, J. et al. (2017) ‘Obstacles and opportunities in Chinese pharmaceutical innovation', Globalization and Health, 13(1), p. 21. Available at: https://doi.org/10.1186/s12992-017-0244-6.
Nugroho;, R. (2015) Policy Making : Mengubah Negara Biasa Menjadi Negara Berprestasi. Elex Media Komputindo. Available at: //10.103.0.43:80%2Findex.php%3Fp%3Dshow_detail%26id%3D520%26keywords%3D (Accessed: 6 November 2023).
Park, H. et al. (2021) ‘A Study on the Impact of R&D Intensity on Business Performance: Evidence from South Korea', Journal of Open Innovation: Technology, Market, and Complexity, 7(2), p. 135. Available at: https://doi.org/10.3390/joitmc7020135.
Peña, O.I.G., Zavala, M.Á.L. and Ruelas, H.C. (2021) ‘Pharmaceuticals Market, Consumption Trends and Disease Incidence Are Not Driving the Pharmaceutical Research on Water and Wastewater', International Journal of Environmental Research and Public Health, 18(5), p. 2532. Available at: https://doi.org/10.3390/ijerph18052532.
PWC (2009) Investing in China's Pharmaceutical Industry. 2nd edn. PricewaterhouseCoopers. Available at: https://www.pwc.com/gx/en/pharma-life-sciences/assets/en-pharma_03-26-small.pdf.
Qiu, L.D., Zhan, C. and Wei, X. (2019) ‘An analysis of the China–US trade war through the lens of the trade literature', Economic and Political Studies, 7(2), pp. 148–168. Available at: https://doi.org/10.1080/20954816.2019.1595329.
Raghupathi, V. and Raghupathi, W. (2020) ‘Healthcare Expenditure and Economic Performance: Insights From the United States Data', Frontiers in Public Health, 8, p. 156. Available at: https://doi.org/10.3389/fpubh.2020.00156.
Rahman, Md.M. and Howlader, Md.S. (2022) ‘The impact of research and development expenditure on firm performance and firm value: evidence from a South Asian emerging economy', Journal of Applied Accounting Research, 23(4), pp. 825–845. Available at: https://doi.org/10.1108/JAAR-07-2021-0196.
Reddy, C.D. and Gupta, N.V. (2013) ‘Overview on Contract Research and Manufacturing Services (CRAMs) and Its Present Status in India', Asian Journal of Pharmaceutical and Clinical Research, 6(2). Available at: https://innovareacademics.in/journal/ajpcr/Vol6Suppl2/1781.pdf.
Sampath, P.G. (2019) Pharmaceutical Manufacturing in Bangladesh – A Success Story. What can we learn? 1. Federation of East African Pharmaceutical Manufacturers (FEAPM), p. 21. Available at: https://strapi.eacgermany.org/uploads/5fda30fc68f07136175100_44e851ba12.pdf.
Sandra, P.S. (2021) R&D intensity as a policy target: main takeaways from 11 international case studies. OECD, p. 36. Available at: http://www.oecd.org/termsandconditions.
Sardella, A. (2023) US Generic Pharmaceutical Industry Economic Instability. US: Center for Analytics and Business Insights & Adjunct Lecturer, Olin Business School Washington University in St. Louis, p. 3.
Scherer, F.M. (2014) ‘Research and Development Costs and Productivity in Biopharmaceuticals', in Encyclopedia of Health Economics. Elsevier, pp. 249–255. Available at: https://doi.org/10.1016/B978-0-12-375678-7.01203-7.
Schuhmacher, A. et al. (2021) ‘R&D efficiency of leading pharmaceutical companies – A 20-year analysis', Drug Discovery Today, 26(8), pp. 1784–1789. Available at: https://doi.org/10.1016/j.drudis.2021.05.005.
Shaikh, M. and Gandjour, A. (2019) ‘Pharmaceutical expenditure and gross domestic product: Evidence of simultaneous effects using a two-step instrumental variables strategy', Health Economics, 28(1), pp. 101–122. Available at: https://doi.org/10.1002/hec.3832.
Siagian, R.C. et al. (2020) ‘A policy-making strategy to forecast outcomes of drug development in Indonesia', International Journal of Health Governance, 25(2), pp. 137–149. Available at: https://doi.org/10.1108/IJHG-12-2019-0083.
Suwantika, A.A. et al. (2020) ‘Cost-Effectiveness Analysis of Spending on Research and Development to Address the Needs for Innovative Therapeutic Products in Indonesia', Therapeutics and Clinical Risk Management, Volume 16, pp. 969–977. Available at: https://doi.org/10.2147/TCRM.S260377.
The Jakarta Post (2018) ‘Pharma companies still dependent on imported APIs, says ministry', The Jakarta Post. Available at: https://www.thejakartapost.com/news/2018/10/18/pharma-companies-still-dependent-on-imported-apis-says-ministry.html.
Theodore, W. et al. (2022) ‘The effects of task environment and organizational agility on perceived managerial discretion and strategy implementation in a pharmaceutical company', International Journal of Pharmaceutical and Healthcare Marketing, 16(2), pp. 204–221. Available at: https://doi.org/10.1108/IJPHM-11-2021-0116.
United Nations (2012) Local production of pharmaceuticals and related technology transfer in developing countries: a series de case studies. New York and Geneva: United Nations.
Warsito, I. (2022) ‘Readiness of Upstream and Downstream Industries in Supporting Independence of Pharmaceutical and Medical Devices'.
Winda, S. (2018) ‘Formularium Nasional (FORNAS) dan e-Catalogue Obat Sebagai Upaya Pencegahan Korupsi dalam Tata Kelola Obat Jaminan Kesehatan Nasional (JKN)', Integritas, 4(2), pp. 177–207.
World Bank (2022) ‘Current Health Expenditure per Capita'. Available at: https://data.worldbank.org/indicator/SH.XPD.CHEX.PC.CD?end=2021&start=2021&view=bar (Accessed: 9 August 2022).
World Health Organization (2017) Indian policies to promote local production of pharmaceutical products and protect public health. Geneva: World Health Organization. Available at: https://apps.who.int/iris/handle/10665/336750 (Accessed: 19 September 2022).
Yang, B., Usman, M. and jahanger, A. (2021) ‘Do industrialization, economic growth and globalization processes influence the ecological footprint and healthcare expenditures? Fresh insights based on the STIRPAT model for countries with the highest healthcare expenditures', Sustainable Production and Consumption, 28, pp. 893–910. Available at: https://doi.org/10.1016/j.spc.2021.07.020.
Copyright (c) 2023 Erwan Hermawan, Nur Anis Hadiyati, Adiarso, Ermawan Darma Setiyadi, Siti Zunuraen, Dudi Hidayat, Anwar Wahyudi
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. As an author you (or your employer or institution) may do the following:
- make copies (print or electronic) of the article for your own personal use, including for your own classroom teaching use;
- make copies and distribute such copies (including through e-mail) of the article to research colleagues, for the personal use by such colleagues (but not commercially or systematically, e.g. via an e-mail list or list server);
- present the article at a meeting or conference and to distribute copies of the article to the delegates attending such meeting;
- for your employer, if the article is a ‘work for hire', made within the scope of your employment, your employer may use all or part of the information in the article for other intra-company use (e.g. training);
- retain patent and trademark rights and rights to any process, procedure, or article of manufacture described in the article;
- include the article in full or in part in a thesis or dissertation (provided that this is not to be published commercially);
- use the article or any part thereof in a printed compilation of your works, such as collected writings or lecture notes (subsequent to publication of the article in the journal); and prepare other derivative works, to extend the article into book-length form, or to otherwise re-use portions or excerpts in other works, with full acknowledgement of its original publication in the journal;
- may reproduce or authorize others to reproduce the article, material extracted from the article, or derivative works for the author's personal use or for company use, provided that the source and the copyright notice are indicated.
All copies, print or electronic, or other use of the paper or article must include the appropriate bibliographic citation for the article's publication in the journal.
2. Requests from third parties
Although authors are permitted to re-use all or portions of the article in other works, this does not include granting third-party requests for reprinting, republishing, or other types of re-use.
3. Author Online Use
- Personal Servers. Authors and/or their employers shall have the right to post the accepted version of articles pre-print version of the article, or revised personal version of the final text of the article (to reflect changes made in the peer review and editing process) on their own personal servers or the servers of their institutions or employers without permission from JAKI;
- Classroom or Internal Training Use. An author is expressly permitted to post any portion of the accepted version of his/her own articles on the author's personal web site or the servers of the author's institution or company in connection with the author's teaching, training, or work responsibilities, provided that the appropriate copyright, credit, and reuse notices appear prominently with the posted material. Examples of permitted uses are lecture materials, course packs, e-reserves, conference presentations, or in-house training courses;
